title: Costimulatory molecule expression on leukocytes from mice with experimental autoimmune encephalomyelitis treated with IFN-beta.
abstract: Interferon-beta (IFN-beta) is of benefit in the treatment of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), but the mechanisms by which it exerts this beneficial effect remain uncertain. The present data demonstrate that IFN-beta therapy impairs the proliferative response to concanavalin A (ConA) and myelin basic protein (MBP), decreases expression of the CD80 molecule on leukocytes of treated mice, and may thereby impede the Th1 cell activation-promoting anergy in EAE. Moreover, IFN-beta therapy increases expression of the CTLA4 molecule, which induces a counterregulatory Th2 response. The reduction of CD80 expression with concomitant increase of CTLA4 expression alters the course of EAE and may be useful as a monitor in therapy with IFN-beta.
authors.affiliation: Neuroimmunology Unit-Department of Microbiology and Immunology, and University of Campinas (UNICAMP), Campinas-SP, Brazil.
authors.forename: Dannie E M
authors.initials: DE
authors.lastname: Hallal
authors.forename: Alessandro S
authors.initials: AS
authors.lastname: Farias
authors.forename: Elaine C
authors.initials: EC
authors.lastname: Oliveira
authors.forename: Blanca Maria
authors.initials: BM
authors.lastname: Diaz-Bardales
authors.forename: Carlos Otavio
authors.initials: CO
authors.lastname: Brandão
authors.forename: Gustavo G
authors.initials: GG
authors.lastname: Protti
authors.forename: Fernanda G
authors.initials: FG
authors.lastname: Pereira
authors.forename: Irene L
authors.initials: IL
authors.lastname: Metze
authors.forename: Leonilda M B
authors.initials: LM
authors.lastname: Santos
mesh_terms: D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000378:metabolism; D018122:B7-1 Antigen / Q000378:metabolism; D060908:CTLA-4 Antigen; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000628:therapy*; D005260:Female; D016899:Interferon-beta / Q000494:pharmacology / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
chemical_list: D015703:Antigens, CD; D000943:Antigens, Differentiation; D018122:B7-1 Antigen; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; D016899:Interferon-beta